Delving into the Latest Updates on Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

TA-CD

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Other Diseases

Active Indication

Cocaine-Related Disorders

Inactive Indication-

Originator Organization

ImmuLogic Pharmaceutical Corp.

Active Organization

ImmuLogic Pharmaceutical Corp.

Inactive Organization

Celtic Pharma Development Services, Inc.Celtic Pharma Capital Ltd.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Objective To compare the effects of the complex triamcinolone acetonide-hydroxypropyl-β-cyclodextrin (TA-CD) on in vitro inflamed primary human articular chondrocytes in the presence or absence of the mixture hyaluronic acid-Chitlac, a lactose-modified chitosan (HA-CTL). Design Changes in cell viability and pro-inflammatory cytokines gene expression were analyzed in human chondrocytes using an in vitro model of macrophage-mediated inflammation. Human monocytes U937 were differentiated to macrophages by phorbol 12-myristate 13-acetate (PMA) and lipopolysaccharides (LPS). The anti-inflammatory effects of the complex TA-CD and HA-CTL mixture were assessed on chondrocytes exposed for 24 hours to U937 conditioned medium (CM), by quantitative polymerase chain reaction analysis. Results The TA-CD viability was enhanced by the presence of the HA-CTL mixture in chondrocyte cultures. The exposure of cells to CM significantly increased interleukin-1β and interleukin-6 gene expression, and when the complex TA-CD was added to the inflamed cells, gene transcription of cytokines was restored to near baseline values, both in the presence or in the absence of HA-CTL mixture. Conclusion The addition of HA-CTL mixture significantly attenuated cytotoxicity induced by TA and preserved the anti-inflammatory effects, thus confirming the chondroprotective role of the HA-CTL mixture.

01 Jul 2021·Journal of Controlled ReleaseQ1 · MEDICINE

Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration

Q1 · MEDICINE

Article

Author: Bhutto, Imran A ; Lutty, Gerard A ; Kambhampati, Siva P ; Ho, Katie ; Kannan, Rangaramanujam M ; Wu, Tony ; McLeod, D Scott

Inflammation and neovascularization are key pathological events in human age-related macular degeneration (AMD). Activated microglia/macrophages (mi/ma) and retinal pigmented epithelium (RPE) play an active role in every stage of disease progression. Systemic therapies that can target these cells and address both inflammation and neovascularization will broaden the impact of existing therapies and potentially open new avenues for early AMD where there are no viable therapies. Utilizing a clinically relevant rat model of AMD that mirrors many aspects that of human AMD pathological events, we show that systemic hydroxyl-terminated polyamidoamine dendrimer-triamcinolone acetonide conjugate (D-TA) is selectively taken up by the injured mi/ma and RPE (without the need for targeting ligands). D-TA suppresses choroidal neovascularization significantly (by >80%, >50-fold better than free drug), attenuates inflammation in the choroid and retina, by limiting macrophage infiltration in the pathological area, significantly suppressing pro-inflammatory cytokines and pro-angiogenic factors, with minimal side effects to healthy ocular tissue and other organs. In ex vivo studies on human postmortem diabetic eyes, the dendrimer is also taken up into choroidal macrophages. These results suggest that the systemic hydroxyl dendrimer-drugs can offer new avenues for therapies in treating early/dry AMD and late/neovascular AMD alone, or in combination with current anti-VEGF therapies. This hydroxyl dendrimer platform but conjugated to a different drug is undergoing clinical trials for severe COVID-19, potentially paving the way for faster clinical translation of similar compounds for ocular and retinal disorders.

01 Sep 2015·European Journal of Pharmaceutics and BiopharmaceuticsQ2 · MEDICINE

Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells

Q2 · MEDICINE

Article

Author: Gerard A. Lutty ; Yumin Oh ; Panagiotis Mastorakos ; Rangaramanujam M. Kannan ; Manoj K. Mishra ; Siva P. Kambhampati

Triamcinolone acetonide (TA) is a potent, intermediate-acting, steroid that has anti-inflammatory and anti-angiogenic activity. Intravitreal administration of TA has been used for diabetic macular edema, proliferative diabetic retinopathy and exudative age-related macular degeneration (AMD). However, the hydrophobicity, lack of solubility, and the side effects limit its effectiveness in the treatment of retinal diseases. In this study, we explore a PAMAM dendrimer-TA conjugate (D-TA) as a potential strategy to improve intracellular delivery and efficacy of TA to target cells. The conjugates were prepared with a high drug payload (∼ 21%) and were readily soluble in saline. Compared to free TA, D-TA demonstrated a significantly improved toxicity profile in two important target [microglial and human retinal pigment epithelium (RPE)] cells. The D-TA was ∼ 100-fold more effective than free TA in its anti-inflammatory activity (measured in microglia), and in suppressing VEGF production (in hypoxic RPE cells). Dendrimer-based delivery may improve the efficacy of TA towards both its key targets of inflammation and VEGF production, with significant clinical implications.

100 Deals associated with Cocaine abuse vaccine TA-CD(ImmuLogic Pharmaceutical)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cocaine-Related Disorders	Phase 2	-	ImmuLogic Pharmaceutical Corp.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00969878 (TA-CD, CTgov)	Phase 2	Cocaine-Related Disorders	300	Placebo Injection (Placebo Injection)	hxdnhtvnpp(avxoujlvne) = tbupzmluzg mqnliraeaj (rgsqtyarbv, epnjydpeiy - xgkqrmcfwp) View more	-	12 Dec 2014
				TA-CD Vaccination (TA-CD Vaccination)	hxdnhtvnpp(avxoujlvne) = wssobidfgk mqnliraeaj (rgsqtyarbv, eeveldrjuu - rxrjienmhk) View more